1,1-dichloro-2-butyne | 139185-44-7

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氯化物
• 英文名称: 1,1-dichloro-2-butyne
• 英文别名: 1,1-dichlorobut-2-yne
• CAS: 139185-44-7
• 化学式: C₄H₄Cl₂
• 分子量: 122.982
• InChiKey: HIBREDQLOHWYLQ-UHFFFAOYSA-N

物化性质

• 沸点：
  138.8±20.0 °C(Predicted)
• 密度：
  1.217±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  6
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  亚甲基环丁烷 、 1,1-dichloro-2-butyne 在 potassium tert-butylate 作用下， 以 正戊烷 为溶剂， 以30%的产率得到1-chloro-1-(propyn-1-yl)spiro<2,3>hexane
  参考文献：
  名称：

  Alkynylhalocarbenes. 2. Generation of (alkyn-1-yl)-chlorocarbenes by basic solvolysis of 1,1-dichloro-2-alkynes and their reaction with olefins: Synthesis of 1-chloro-1-alkynylcyclopropanes

  摘要：

  1,1-Dichloro-2-alkynes R1C=CCHCl2 (4a-g; R1 = Me, n-Pr, c-Pr, t-Bu, Ad, Nor, Ph) were synthesized with yield of 50-75% by chlorination with PCl5 of formylacetylenes (3a-g), prepared by oxidation of propargyl alcohols (1a-d) with CrO3.Py.HCl complex or acidolysis of propargyl acetals (2a-c) in the presence of catalytic quantities of pyridine; the corresponding alkynylchlorocarbenes, R1C=CCCl (5a-g) were generated from them with powdered KOH in a two-phase system or t-BuOK. The latter were trapped by olefins with formation of 1-chloro-1-alkynylcyclopropanes (6a-t) with yields of up to 90%.

  DOI：

  10.1007/bf00864534
• 作为产物：
  描述：

  2-丁炔-1-醇 在 吡啶 、 CrO₃*pyridinium hydrochloride 、 五氯化磷 作用下， 生成 1,1-dichloro-2-butyne
  参考文献：
  名称：

  Shavrin, Konstantin N.; Krylova, Irina V.; Shvedova, Inna B., Journal of the Chemical Society. Perkin transactions II, 1991, # 12, p. 1875 - 1882

  摘要：

  DOI：

文献信息

• [EN] DIMERIC COMPOUNDS OF PIPERIDINE, PIPERAZINE OR MORPHOLINE OR THEIR 7-MEMBERED ANALOGS SUITABALE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS<br/>[FR] COMPOSES DIMERES DE PIPERIDINE, PIPERAZINE OU MORPHOLINE OU LEURS PRODUITS ANALOGUES A 7 ELEMENTS, DESTINES AU TRAITEMENT DE MALADIES NEURODEGENERATIVES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2006008259A1

  公开（公告）日：2006-01-26

  Formula (I’’), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof.

  公式(I'')，N-氧化物形式，药用可接受的增加盐和它们的立体化学异构形式。
• [EN] AZABICYCLO (3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS<br/>[FR] DERIVES AZABICYCLO (3.1.0) HEXANE UTILES COMME MODULATEURS DES RECEPTEURS D3 DE LA DOPAMINE
  申请人：GLAXO GROUP LTD

  公开号：WO2005080382A1

  公开（公告）日：2005-09-01

  The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl; or corresponds to a group R5; R2 is hydrogen or C1-4alkyl; R3 is C1-4alkyl; R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; R5 is a moiety selected from the group consisting of: isoxazolyl, -CH2-N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl; and when R1 is chlorine and p is 1, such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R1 corresponds to R5, p is 1; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency or as antipsychotic agents.

  本发明涉及公式(I)的新化合物或其药学上可接受的盐，其中G选自以下组成的一组：苯基、吡啶基、苯并噻唑基、吲哚基；p是一个从0到5的整数；R1独立地选自以下组成的一组：卤素、羟基、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、C1-4烷酰基；或对应于一个R5基团；R2是氢或C1-4烷基；R3是C1-4烷基；R4是氢，或苯基、杂环基、5-或6-成员杂芳基，或8-到11-成员双环基，其中任何一个基团可以选择地被来自以下组成的1、2、3或4个取代基所取代：卤素、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、C1-4烷酰基；R5是选自以下组成的基团：异噁唑基、-CH2-N-吡咯基、1,1-二氧化-2-异噻唑啉基、噻吩基、噻唑基、吡啶基、2-吡咯烷基，这样的基团可以选择地被一个或两个取代基所取代，所述取代基选自：卤素、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、C1-4烷酰基；当R1是氯且p为1时，该R1不位于与分子其余部分的连接键的邻位；当R1对应于R5时，p为1；它们的制备方法，用于这些方法的中间体，含有它们的药物组合物以及它们作为多巴胺D3受体调节剂在治疗中的用途，例如用于治疗药物依赖或作为抗精神病药物。
• [EN] BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF<br/>[FR] DÉRIVÉS D'ACIDE BORONIQUE ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：REMPEX PHARMACEUTICALS INC

  公开号：WO2016149393A1

  公开（公告）日：2016-09-22

  Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.

  本文揭示了抗微生物化合物组合物、药物组合物及其使用和制备。一些实施例涉及硼酸衍生物及其作为治疗剂的使用。
• [EN] 8-AZABICYCLO[3.2.1]OCTANE ETHER DERIVATIVES AND THEIR USE AS NEUROKININ RECEPTOR ANTAGONISTS<br/>[FR] DERIVES D'ETHER 8-AZABICYCLO[3.2.1]OCTANE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DE RECEPTEUR DE NEUROKININE
  申请人：MERCK SHARP & DOHME

  公开号：WO2004031185A1

  公开（公告）日：2004-04-15

  The present invention relates compounds of the formula (I) : wherein X represents hydrogen, C1-4alkyl optionally substituted by a hydroxy, methoxy or benzyloxy group, or CO2(C1-2alkyl); Z is -CR9R10CH2- or -CH2CR9R10-; and R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migaine, emesis or postherpetic neuralgia.

  本发明涉及以下式(I)的化合物：其中X代表氢，C1-4烷基，可选择地被羟基，甲氧基或苄氧基取代，或CO2(C1-2烷基)；Z为-CR9R10CH2-或-CH2CR9R10-；而R1、R2、R3、R4、R5和R6如本文所定义。这些化合物在治疗或预防抑郁症、焦虑、疼痛、炎症、偏头痛、呕吐或带状疱疹后神经痛方面具有特殊用途。
• [EN] MODULATORS OF CULLIN 3 ADAPTOR KBTBD4 AS ANTI-CANCER COMPOUNDS<br/>[FR] MODULATEURS DE L'ADAPTATEUR DE CULLIN 3 KBTBD4 EN TANT QUE COMPOSÉS ANTICANCÉREUX
  申请人：UNIV MONTREAL

  公开号：WO2021119834A1

  公开（公告）日：2021-06-24

  It is provided the use of Pyrimido[4,5-B]indole derivatives as anti-cancer compounds, and more specifically the use of UM171 and its derivatives for treating cancer, by activating the CULLIN3-RING ubiquitin ligase complex which degrades RCOR1 which normally acts as the scaffolding protein for the RCOR1/LSD1 and HDAC2 complex, itself being dissociated in the presence of UM171. Thus UM171 acts like a molecular glue degrader, inhibiting HDACs, RCOR1, CoREST and LSD1 and resulting in an anti-cancer activity.

  提供使用嘧啶并[4,5-B]吲哚衍生物作为抗癌化合物，更具体地使用UM171及其衍生物来治疗癌症，通过激活CULLIN3-RING泛素连接酶复合物，降解通常作为RCOR1/LSD1和HDAC2复合物支架蛋白的RCOR1，本身在UM171存在时被解离。因此，UM171起到分子粘合蛋白降解剂的作用，抑制HDACs、RCOR1、CoREST和LSD1，从而产生抗癌活性。